Bajaj Healthcare gets NCLT nod for Genrx acquisition

Bajaj Healthcare received approval from the National Company Law Tribunal’s Mumbai Bench for the acquisition of Genrx Pharmaceuticals Private Limited on a going concern basis. The order was passed and downloaded by the company on 13 Oct 2026, while the disclosure was published on 14 Oct 2026. The transaction follows the company’s earlier disclosures from April 2025 regarding the proposed acquisition of the entity, which is currently in liquidation. ⚖️

Under the terms approved by the tribunal, Genrx Pharmaceuticals will become a wholly owned subsidiary of Bajaj Healthcare. The approval is subject to implementation of the specific terms set out in the NCLT order. The order remains effective from 13 Oct 2026 until the tribunal issues any further order or direction. The company said it will take the necessary actions in accordance with the approved terms.

The development removes a key legal approval requirement for the proposed transaction and gives the acquisition a defined implementation framework. However, the available disclosure does not specify the acquisition consideration, the assets or liabilities being assumed, the expected revenue contribution, or the timeline for operational integration. Those details will be important for assessing the transaction’s financial impact on the pharmaceutical manufacturer. 💊

NCLT approval is the immediate corporate catalyst, but the next market-relevant information is likely to come from filings on completion of the acquisition, the effective transfer of Genrx’s business, and any funding or accounting treatment. Traders will also watch for details on Genrx’s product portfolio, manufacturing capacity, regulatory status and contribution to Bajaj Healthcare’s consolidated results. 📌

The acquisition is part of an earlier process first disclosed in April 2025 and concerns a company in liquidation. The going-concern structure indicates that the business is intended to continue as an operating entity after the transaction, subject to the tribunal-approved terms; the disclosure does not quantify the assets or operations that will transfer. Any subsequent filing confirming completion or providing financial details would give the market a clearer basis to assess the deal’s effect on the pharmaceutical sector and on Bajaj Healthcare’s earnings profile.

Source: scanx.trade, 14 Oct 2026

Not investment advice. For informational purposes only.